Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of envafolimab + lenvatinib + TACE for conversion treatment of inoperable hepatocellular carcinoma
ChiCTR2400081945Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Mar 2024
- Modality
- Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Conversion rate. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
envafolimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400081945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081945.